Starting 22nd May 2018
Non-alcoholic fatty liver disease (NAFLD) is emerging as the most common cause of liver disease worldwide, with its prevalence in Australia estimated at 30%.
NAFLD is the hepatic manifestation of metabolic syndrome, with a strong link to insulin resistance and obesity. As this is largely a lifestyle disease, there are multiple interventions that can be discussed within the pharmacy setting to assist in improving these customers’ well-being. This lecture teaches more about NAFLD and what options are available to prevent and manage this common illness. BioCeuticals is honoured to announce A/Prof. Martin Weltman as our guest speaker at this special event. A/Prof. Weltman is a leading gastroenterologist specialising in NAFLD, having researched and practiced clinically in the NAFLD space for over 20 years. His research published in the 1990s on the subject fundamentally changed the thinking of the medical fraternity on this disease and continues to be heavily cited.
|6:00pm - 6:30pm||Registration & Buffet Dinner|
|6:30pm - 7:30pm||Session 1|
|7:30pm – 7:45pm||Break|
|7:45pm – 8:30pm||Session 2|